BIO-TECHNE Corp Financials
Quarterly XBRL submissions from SEC 10-K and 10-Q filings.
Income Statement (Last 8 Quarters)
(3)| Period | Revenue | YoY % | Net Income | YoY % | Operating Income | EPS |
|---|---|---|---|---|---|---|
| Q1 FY202610-Q · 2025-09-30 | $286.6M | — | $38.2M | — | $47.7M | $0.24 |
| Q3 FY202510-Q · 2025-03-31 | $316.2M | — | $22.6M | — | $38.7M | $0.14 |
| Q2 FY202510-Q · 2024-12-31 | $27.4M | — | $34.9M | — | $90.4M | $0.22 |
Balance Sheet
| Period | Total Assets | Total Liabilities | Cash & Equivalents | Shareholders Equity |
|---|---|---|---|---|
| Q1 FY202610-Q | $2.5B | — | $145.0M | — |
| Q3 FY202510-Q | $2.6B | — | $140.7M | $2.0B |
| Q2 FY202510-Q | $2.7B | — | $177.5M | -$90.7M |
Cash Flow Highlights
| Period | Operating Income | Net Income | Gross Profit | Shares Outstanding |
|---|---|---|---|---|
| Q1 FY202610-Q | $47.7M | $38.2M | $188.1M | 155,749,477 |
| Q3 FY202510-Q | $38.7M | $22.6M | $214.6M | 156,761,000 |
| Q2 FY202510-Q | $90.4M | $34.9M | $193.9M | 157,915,999 |
Filings
(4)Methodology
Every figure on this page is pulled directly from BIO-TECHNE Corp's own XBRL submissions to the U.S. Securities and Exchange Commission. XBRL is the standardized tagging format the SEC requires for line items in 10-K and 10-Q filings, which means revenue, net income, and balance-sheet entries are reported by the company itself — not estimated by us.
Cayman Journal reconciles preferred GAAP tags (for example, Revenues, RevenueFromContractWithCustomerExcludingAssessedTax) and normalizes them so quarter-over-quarter comparability is preserved. Our automated ingestion runs nightly; markets editors spot-check flagged anomalies before they appear on the public hub. Where a tag is missing for a given period, we surface an em dash rather than impute a value.
Source documents are linked under Filings above and point to the original EDGAR submission index. Errors should be reported to [email protected].